Abbott finishes strongly before spin-off

Abbott has presented its full-year results for 2012 – the last in which many of its products will appear, following the AbbVie split-off earlier this month. While sales for the combined entity f…

---

After 125 years, ‘old’ Abbott posts final set of financials

After 125 years, 'old' Abbott posts final set of financials…

---

Financial Report: Abbott

Debt resolution impacts earnings…

---

Abbott initiates clinical trial of Absorb TM in the United States

Abbott (NYSE: ABT) announced today the initiation of the ABSORB III clinical trial in patients in the United States. This randomized, controlled trial is designed to enroll approximately 2,250 patient…

---